Tylenol Leads OTC Acetaminophen Sales Surge After Ibuprofen Scare During Pandemic – IRI
J&J leads sales growth in OTC pain relief and allergy categories in 2020 as its brands benefited from competing products’ problems and COVID-19’s impact of consumer habits. IRI reveals winning brands that kept a focus on maintaining health in 2020.
You may also be interested in...
Studies On Treating COVID-19 Inflammation And Migraines Also Weigh Efficacy Of Remote Trials
Preliminary data from Cold Springs Harbor Laboratory study suggest famotidine could mitigate inflammatory symptoms of COVID-19 in adults. Research sponsored by Nestle Health Science in Canada also points to remote studies likely to continue after emerging as a pandemic innovation.
With Spring's Arrival, OTC Allergy Ad Campaigns Bloom In US For Claritin, Flonase
Bayer launches multi-year campaign “Outsideologist Project” for Claritin to offer parents fun ways to get their children outside. GSK’s “Change the Game” campaign for Flonase as official allergy relief partner of MLB has new spokesman.
J&J’s Consumer Health Product Sales Slump In Comparison A Year After COVID-19 Stockpiling
Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.